Related Experiment Video
Updated: Jun 3, 2026
10:10
Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents
Published on: February 15, 2022
[Cannabinoid applications in glaucoma]
S Pinar-Sueiro1, R Rodríguez-Puertas, E Vecino
1Departamento de Biología Celular e Histología, Grupo de Oftalmo-Biología Experimental (GOBE), Facultad de Medicina, Universidad del País Vasco (UPV/EHU), Leioa, Vizcaya, España.
Archivos De La Sociedad Espanola De Oftalmologia
|March 19, 2011
Summary
Cannabinoid agonists show promise for glaucoma treatment, offering both reduced intraocular pressure and neuroprotection for retinal ganglion cells. Further clinical studies are needed to confirm their safety and efficacy in practice.
Area of Science:
- Ophthalmology
- Pharmacology
- Neuroscience
Background:
- Glaucoma is a leading cause of irreversible blindness due to progressive optic neuropathy.
- Current medical treatments for glaucoma are limited, necessitating research into novel therapeutic approaches.
- Cannabinoid agonists are being investigated as a potential new treatment for glaucoma.
Purpose of the Study:
- To review existing scientific literature on the therapeutic effects of cannabinoids for glaucoma.
- To evaluate different administration methods of cannabinoids for glaucomatous optic neuropathy.
Main Methods:
- Investigated the expression of cannabinoid receptors (CB1 and CB1) in ocular tissues.
- Examined the effects of cannabinoid agonists on intraocular pressure (IOP) regulation.
- Assessed the neuroprotective potential of cannabinoids on retinal ganglion cells.
Main Results:
- Cannabinoid agonists demonstrated significant hypotensive effects, reducing intraocular pressure.
- Experimental studies showed neuroprotective benefits of cannabinoids on retinal ganglion cells.
- Specific agonists like WIN 55212-2 and anandamide exhibited good tolerability with topical application.
Conclusions:
- Cannabinoid agonists, such as WIN 55212-2 and anandamide, show potential as ideal glaucoma treatments.
- These compounds effectively reduce IOP and offer neuroprotection to retinal cells.
- Further clinical trials are essential to validate safety and efficacy for clinical practice.
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:25Glaucoma: Overview
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
01:28Angle Closure Glaucoma: Treatment
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
01:21Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
01:23Ophthalmic Drug Delivery Systems
Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
01:22Drug Delivery: Miscellaneous Routes
Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection, and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs through the...
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs through the...